PEDRO
PÉREZ SEGURA
Profesor asociado de Ciencias de la Salud
![Foto de PEDRO](/img/nophoto.png)
![Foto de Hospital Regional Universitario de Málaga](/img/noimage_org.png)
Hospital Regional Universitario de Málaga
Málaga, EspañaPublicacions en col·laboració amb investigadors/es de Hospital Regional Universitario de Málaga (12)
2023
2021
-
SEOM clinical guideline for management of adult medulloblastoma (2020)
Clinical and Translational Oncology, Vol. 23, Núm. 5, pp. 940-947
2018
-
Correction to: SEOM clinical guidelines for anaplastic gliomas (2017) (Clinical and Translational Oncology, (2018), 20, 1, (16-21), 10.1007/s12094-017-1762-7)
Clinical and Translational Oncology
-
SEOM clinical guidelines for anaplastic gliomas (2017)
Clinical and Translational Oncology, Vol. 20, Núm. 1, pp. 16-21
2017
-
Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification
Neuro-Oncology, Vol. 19, Núm. 11, pp. 1522-1531
2016
-
GEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status
Clinical and Translational Oncology, Vol. 18, Núm. 8, pp. 805-812
-
Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma
Anti-Cancer Drugs, Vol. 27, Núm. 2, pp. 133-137
2014
-
Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry
Journal of Neuro-Oncology, Vol. 116, Núm. 2, pp. 413-419
-
Erratum: Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry [J Neurooncol, 116, (2014), 413-419, DOI 10.1007/s11060-013-1316-y]
Journal of Neuro-Oncology
-
Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain
Clinical and Translational Oncology, Vol. 16, Núm. 3, pp. 273-279
2012
-
Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO)
Anti-Cancer Drugs, Vol. 23, Núm. 6, pp. 659-665
2011
-
Melanoma heredo-familiar
Revisiones en Cancer, Vol. 25, Núm. 4, pp. 166-171